United States · Funded startup
Funding summaryUpdated 26 Oct 2026
$248Mraised across 4 rounds since 2014, from 4 sources
Each circle is a round, placed by date and sized by amount. The line above is the running total.
Source recordedSEC filing: $125M sold, first sale May 2025
Reported by Pharmanewsdaily
OrbiMed
Foresite Capital
The Column Group
EcoR1 Capital
Topspin PartnersFrom a historical funding record
No investor was named in the report.
From a historical funding record
From ORIC Pharmaceuticals's own website: 5 on the team.
The busiest backers across the latest rounds. A filled square is a round they joined; a dark one, a round they led.
Foresite Capital
InvusL
ArrowMark PartnersL
New Enterprise AssociatesOrbiMed
Vivo Capital
SR One
Casdin CapitalThe Column GroupEcoR1 CapitalMissing a round, or an investor who was in one? Tell us.
These 4 firms list ORIC Pharmaceuticals as a portfolio company on their own websites, but no report of a round names them. They are the firms' own claims, kept apart from the rounds above.
ORIC Pharmaceuticals's investors include Foresite Capital, Invus, ArrowMark Partners, New Enterprise Associates and OrbiMed, and 8 more on record.
ORIC Pharmaceuticals has raised $248M across 4 rounds since 2014.
ORIC Pharmaceuticals's most recent round was an Undisclosed round of $125M in May 2025.
Its most recent round, $125M in May 2025, is also its largest on record.
ORIC Pharmaceuticals's first round on record, in Dec 2015, was backed by OrbiMed, Foresite Capital and The Column Group and 3 others.
ORIC Pharmaceuticals's latest named round is an Undisclosed round, in May 2025.
ORIC Pharmaceuticals is based in the United States.
Invus led the Series D in 2019.
In the same sector, and raised in the last eighteen months.
Search every investor by what they have actually funded, then narrow to your stage and market. Free.
United States · 
